Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body

Ab­b­Vie will spend $700 mil­lion up­front, plus fu­ture pay­ments, on a trispe­cif­ic an­ti­body for blood can­cer from IGI Ther­a­peu­tics, adding to a slow but steady …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.